Edition:
India

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

2.81USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
52,804
52-wk High
$7.68
52-wk Low
$1.84

Chart for

About

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $95.15
Shares Outstanding(Mil.): 34.35
Dividend: --
Yield (%): --

Financials

BRIEF-Sunesis Pharmaceuticals Announces Cancellation Of Presentation And Webcast At Cowen & Company 38Th Annual Health Care Conference

* SUNESIS PHARMACEUTICALS ANNOUNCES CANCELLATION OF PRESENTATION AND WEBCAST AT COWEN & COMPANY 38TH ANNUAL HEALTH CARE CONFERENCE

13 Mar 2018

BRIEF-Sunesis Pharma Qtrly Loss Per Share $0.21

* SUNESIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

09 Mar 2018

BRIEF-Boxer Capital Llc Reports 6.2 Percent Passive Stake In Sunesis Pharmaceuticals Inc

* BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SUNESIS PHARMACEUTICALS INC AS OF FEBRUARY 21, 2018 Source text: (http://bit.ly/2H6YWUT) Further company coverage:

06 Mar 2018

BRIEF-Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017

* SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017

05 Dec 2017

BRIEF-Sunesis Pharmaceuticals Appoints William Quinn As CFO

* SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT

30 Nov 2017

BRIEF-RA Capital Management reports 10.4 pct passive stake in Sunesis Pharmaceuticals as of Oct 25

* RA Capital Management reports 10.4 percent passive stake in Sunesis Pharmaceuticals as of October 25 – SEC Filing‍​ Source text: [http://bit.ly/2yZzSQ5] Further company coverage:

14 Nov 2017

BRIEF-Sunesis Pharmaceuticals Inc Q3 loss per share ‍$0.43​

* Sunesis Pharmaceuticals reports third quarter 2017 financial results and recent highlights

02 Nov 2017

Competitors

Earnings vs. Estimates